7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      In vivo neuroimaging and behavioral correlates in a rat model of chemotherapy-induced cognitive dysfunction.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Adjuvant chemotherapy has been used for decades to treat cancer, and it is well known that disruptions in cognitive function and memory are common chemotherapeutic adverse effects. However, studies using neuropsychological metrics have also reported group differences in cognitive function and memory before or without chemotherapy, suggesting that complex factors obscure the true etiology of chemotherapy-induced cognitive dysfunction (CICD) in humans. Therefore, to better understand possible mechanisms of CICD, we explored the effects of CICD in rats through cognition testing using novel object recognition (NOR) and contextual fear conditioning (CFC), and through metabolic neuroimaging via [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET). Cancer-naïve, female Sprague-Dawley rats were administered either saline (1 mL/kg) or doxorubicin (DOX) (1 mg/kg in a volume of 1 mL/kg) weekly for five weeks (total dose = 5 mg/kg), and underwent cognition testing and PET imaging immediately following the treatment regime and 30 days post treatment. We did not observe significant differences with CFC testing post-treatment for either group. However, the chemotherapy group exhibited significantly decreased performance in the NOR test and decreased (18)F-FDG uptake only in the prefrontal cortex 30 days post-treatment. These results suggest that long-term impairment within the prefrontal cortex is a plausible mechanism of CICD in this study, suggesting DOX-induced toxicity in the prefrontal cortex at the dose used.

          Related collections

          Author and article information

          Journal
          Brain Imaging Behav
          Brain imaging and behavior
          Springer Nature
          1931-7565
          1931-7557
          Jan 20 2017
          Affiliations
          [1 ] Vanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center, Nashville, TN, USA. Robert.Barry@mgh.Harvard.edu.
          [2 ] Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, USA. Robert.Barry@mgh.Harvard.edu.
          [3 ] Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, MA, USA. Robert.Barry@mgh.Harvard.edu.
          [4 ] Department of Radiology, Harvard Medical School, Boston, MA, USA. Robert.Barry@mgh.Harvard.edu.
          [5 ] Vanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center, Nashville, TN, USA.
          [6 ] Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, TN, USA.
          [7 ] Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN, USA.
          [8 ] Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, USA.
          [9 ] Neuroscience Program, Vanderbilt University, Nashville, TN, USA.
          [10 ] Division of Animal Care, Vanderbilt University Medical Center, Nashville, TN, USA.
          [11 ] Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, TN, USA.
          [12 ] Department of Biomedical Engineering, Vanderbilt University, Nashville, TN, USA.
          [13 ] Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA.
          Article
          10.1007/s11682-017-9674-2
          10.1007/s11682-017-9674-2
          28108946
          b8895b65-98ef-48d8-9b4d-2c0703fe1fb2
          History

          Chemobrain,Chemotherapy,Chemotherapy-induced cognitive dysfunction,Contextual fear conditioning,Doxorubicin,Neurobehavioral testing,Neuroimaging,Novel object recognition,[18F]fluorodeoxyglucose positron emission tomography

          Comments

          Comment on this article